LONGEVERON
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. This is through the testing of allogeneic human Mesenchymal Stem Cells (MSCs) that are derived from the bone marrow of young, healthy donors. The Longeveron-grown Mesenchymal Stem Cell (LMSCs) product is manufactured in Longeveron’s cell processing facility located in Miami, Florida.
LONGEVERON
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2014-01-01
Address:
Miami, Florida, United States
Country:
United States
Website Url:
http://www.longeveron.com
Total Employee:
11+
Status:
Active
Contact:
305.909.0840
Total Funding:
9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Sitelinks Search Box Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alzheimer's Association
Alzheimer's Association investment in Grant - Longeveron
National Institutes of Health
National Institutes of Health investment in Grant - Longeveron
TEDCO
TEDCO investment in Grant - Longeveron
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-09 | Longeveron Announces CEO Transition - May 09, 2022 |
| 2022-04-05 | Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer |
Official Site Inspections
http://www.longeveron.com Semrush global rank: 6.6 M Semrush visits lastest month: 934
- Host name: cloudhost-4388385.us-midwest-2.nxcli.net
- IP address: 192.190.220.86
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Longeveron"
Longeveron® Announces World Health Organization Approval of ...
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life …See details»
About Us - Longeveron
Longeveron’s corporate headquarters and manufacturing facilities are located in the Converge Miami Building in Miami, Florida. This state-of-the-art GMP facility consists of 3,000 ft2 of …See details»
Longeveron® Announces Full-Year 2024 Financial Results and …
Feb 28, 2025 Longeveron’s investigational therapeutic candidate is Lomecel-B™, a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications. In February 2025, …See details»
Longeveron - Crunchbase Company Profile & Funding
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Longeveron's primary investigational …See details»
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 …
8 hours ago Wa'el Hashad, CEO, Longeveron. Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy. Stem cell therapy laromestorcel being …See details»
Longeveron® Named XPRIZE Healthspan Semifinalist and Top
19 hours ago Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is …See details»
History - Longeveron
Longeveron was founded on the premise that the very cells within our bodies whose primary function is to repair, restore and regenerate damaged tissue and organs may be developed into a safe and effective “off-the-shelf” cell therapy …See details»
Longeveron - The Org
Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.See details»
Longeveron® Announces World Health Organization Approval of ...
Feb 18, 2025 Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™ Longeveron Tue, …See details»
Longeveron® Announces First Quarter 2025 Financial Results and …
3 days ago Development Programs Update Longeveron’s investigational therapeutic candidate is laromestrocel (Lomecel-B™), a proprietary, scalable, allogeneic cellular therapy being …See details»
Longeveron® Announces World Health Organization Approval of
Feb 18, 2025 Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.See details»
Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan …
8 hours ago Longeveron Inc., a clinical-stage biotechnology company, has been named a Top 40 Semifinalist in the XPRIZE Healthspan competition, earning a $250,000 Milestone 1 Award. …See details»
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40
8 hours ago Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. Read MoreSee details»
Longeveron® Announces First Quarter 2025 Financial Results
3 days ago Longeveron’s investigational therapeutic candidate is laromestrocel (Lomecel-B™), a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications. In …See details»
Leadership - Longeveron
ABOUT US LEADERSHIP Wa'el Hashad Chief Executive Officer Wa’el Hashad joined Longeveron Inc. as Chief Executive Officer in March, 2023, bringing with him more than 35 …See details»
Longeveron Issues Letter to Shareholders Highlighting Corporate ...
Apr 8, 2024 Longeveron's foundation in cutting-edge cellular therapy research, coupled with the promise of Lomecel-B TM , positions us to profoundly impact patients’ lives for the better by …See details»
Longeveron LLC - VentureRadar
"We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is …See details»
Longeveron® Announces World Health Organization Approval of …
Feb 18, 2025 --Longeveron Inc., a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today …See details»
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 …
8 hours ago About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead …See details»
Longeveron® Announces First Quarter 2025 Financial Results and …
3 days ago Longeveron’s investigational therapeutic candidate is laromestrocel ... In February 2025, the International Nonproprietary Names (INN) Expert Committee of the World Health …See details»